A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients

Relapsed Ovarian Cancer Clinical Trial

Official title:
A Phase 2 Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in the Treatment of Relapsed Ovarian Cancer Patients

Status Recruiting

Clinical Trial Summary

This is a multicenter, randomized, open-label, 2-arm Phase 2 study to evaluate the efficacy and safety of Fluzoparib with Apatinib versus Fluzoparib alone, as treatment, in relapsed ovarian cancer patients. The study contains a Safety Lead-in Phase in which the safety and tolerability of Fluzoparib+Apatinib will be assessed prior to the Phase 2 portion of the study.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04517357
Study type	Interventional
Source	Jiangsu HengRui Medicine Co., Ltd.
Contact	Quanren Wang
Phone	+86 18036618570
Email	quanren.wang@hengrui.com
Status	Recruiting
Phase	Phase 2
Start date	October 16, 2020
Completion date	March 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT01874353` - Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy	Phase 3
Not yet recruiting	`NCT06081595` - Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment	Phase 2
Recruiting	`NCT04887961` - Reprab Study: PLD + Trabectedin Rechallenge	Phase 2
Active, not recruiting	`NCT03534453` - Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy	Phase 3
Recruiting	`NCT05080556` - Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer	Phase 2
Recruiting	`NCT05607329` - Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Maintenance Treatment: a Multicentre, Open-label, Randomised, Phase 3 Trial	N/A
Terminated	`NCT04999605` - A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer	Phase 1/Phase 2
Completed	`NCT02825420` - Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients
Recruiting	`NCT04713514` - OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC	Phase 2
Not yet recruiting	`NCT05479487` - Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment	Phase 2